This approach has yielded fruitful results in preclinical glioma models, as shown by the development of tandem CAR T cells that bind HER2 and IL13Rα2 [143], as well as trivalent CAR T cells targeting HER2, IL13Rα2 and EphA2 [144]. The gene discussed is EPHA2; the disease is central nervous system cancer.